Prognostic Value of DNA Ploidy, bcl-2 and p53 in Localized Prostate Adenocarcinoma Incidentally Discovered at Transurethral Prostatectomy

Journal of Urology

Volumn 176, Issue 6, 2006, Pages 2701-2705

  Abaza, Ronney ^a   Diaz Jr , Leslie K ^a   Laskin, William B ^a   Pins, Michael R ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

adenocarcinoma; gene expression; incidental findings; prostate; transurethral resection of prostate

Indexed keywords

PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; ANEUPLOIDY; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CELL CYCLE; CLINICAL ARTICLE; CORRELATION ANALYSIS; DECISION MAKING; FLOW CYTOMETRY; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MULTIVARIATE ANALYSIS; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REGRESSION ANALYSIS; STATISTICAL ANALYSIS; TIME SERIES ANALYSIS; TRANSURETHRAL RESECTION; TUMOR GROWTH; UNIVARIATE ANALYSIS;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; INCIDENTAL FINDINGS; MALE; MIDDLE AGED; PLOIDIES; PROGNOSIS; PROSTATECTOMY; PROSTATIC DISEASES; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 33751027185     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2006.07.133     Document Type: Article

References (20)

1. van Andel G., Vleeming R., Kurth K., and de Reijke T.M. Incidental carcinoma of the prostate. Semin Surg Oncol 11 (1995) 36
2. Bostwick D.G. The pathology of incidental carcinoma. Cancer Surv 23 (1995) 7
3. Brewster S.F., Oxley J.D., Trivella M., Abbott C.D., and Gillatt D.A. Preoperative p52, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy. J Urol 161 (1999) 1238
4. Fox S.B., Persad R.A., Royds J., Kore R.N., Silcocks P.B., and Collins C.C. P53 and c-myc expression in stage A1 prostatic adenocarcinoma: useful prognostic determinants?. J Urol 150 (1993) 490
5. Bauer J.J., Sesterhenn I.A., Mostofi F.K., McLeod D.G., Srivastava S., and Moul J. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J Urol 156 (1996) 1511
6. Borre M., Hoyer M., Nerstrom B., and Overgaard J. DNA ploidy and survival of patients with clinically localized prostate cancer treated without intent to cure. Prostate 36 (1998) 244
7. Zincke H., Bergstralh E.J., Larson-Keller J.J., Farrow G.M., Myers R.P., Lieber M.M., et al. Stage D1 prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment. Evidence for favorable survival in patients with DNA diploid tumors. Cancer 70 (1992) 311
8. Egevad L., Granfors T., Karlberg L., Bergh A., and Stattin P. Prognostic value of the Gleason score in prostate cancer. BJU Int 89 (2002) 538
9. Grizzle W.E., Myers R.B., Manne U., and Srivastava S. Immunohistochemical evaluation of biomarkers in prostatic and colorectal neoplasia. In: Hanausek M., and Walaszek Z. (Eds). Tumor Marker Protocols (1998), Humana Press, Totowa, New Jersey 143 chapt. 9
10. Erbersdobler A., Fritz H., Schnoger S., Graefen M., Hammerer P., Huland H., et al. Tumour grade, proliferation, apoptosis, microvessel density, p53, and bcl-2 in prostate cancers: differences between tumours located in the transition zone and in the peripheral zone. Eur Urol 41 (2002) 40
11. Stackhouse G.B., Sesterhenn I.A., Bauer J.J., Mostofi F.K., Connelly R.R., Srivastava S.K., et al. p53 and BCL-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy. J Urol 162 (1999) 2040
12. Borre M., Stausbol-Gron B., and Overgaard J. p53 accumulation associated with bcl-2, the proliferation marker MIB-1 and survival in patients with prostate cancer subjected to watchful waiting. J Urol 164 (2000) 716
13. Navone N.M., Troncoso P., Pisters L.L., Goodrow T.L., Palmer J.L., Nichols W.W., et al. p53 Protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 85 (1993) 1657
14. Kallakury B.V., Figge J., Ross J.S., Fisher H.A., Figge H.L., and Jennings T.A. Association of p53 immunoreactivity with high Gleason tumor grade in prostate adenocarcinoma. Hum Pathol 25 (1994) 92
15. Stattin P., Bergh A., Karlberg L., Nordgren H., and Damber J.E. p53 Immunoreactivity as prognostic marker for cancer-specific survival in prostate cancer. Eur Urol 30 (1996) 65
16. Colombel M., Symmans G., Gil S., O'Toole K., Chopin D., Benson M., et al. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancer. Am J Pathol 143 (1993) 390
17. Lipponen P., and Vesalainen S. Expression of the apoptosis suppressing protein bcl-2 in prostatic adenocarcinoma is related to tumour malignancy. Prostate 32 (1997) 9
18. Mattfeldt T., Trijic D., Gottfried H.W., and Kestler H.A. Incidental carcinoma of the prostate: Clinicopathological, stereological, and immunohistochemical findings studied with logistical regression and self-organizing feature maps. BJU Int 93 (2004) 284
19. Shankey T.V., Kallioniemi O.P., Koslowski J.M., Lieber M.L., Mayall B.H., Miller G., et al. Consensus review of the clinical utility of DNA content cytometry in prostate cancer. Cytometry 14 (1993) 497
20. McIntire T.L., Murphy W.M., Coon J.S., Chandler R.W., Schwartz D., Conway S., et al. The prognostic value of DNA ploidy combined with histologic substaging for incidental carcinoma of the prostate gland. Am J Clin Pathol 89 (1988) 370